How interferon signals affect insulin-producing cells in type 1 diabetes
Interferon Signaling in the T1D Islet Microenvironment
['FUNDING_U01'] · UNIVERSITY OF CHICAGO · NIH-11135898
This project looks at how immune-system interferon proteins change insulin-producing beta cells in people with or at risk for type 1 diabetes.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11135898 on ClinicalTrials.gov |
What this research studies
From my point of view, the team is studying how interferons—immune proteins released during inflammation—alter the behavior of insulin-making beta cells in the pancreas. They combine analysis of human islet tissue, genetic risk factors, and molecular pathways that control mRNA translation and protein modification to see how short-term versus sustained interferon exposure affects cells. The researchers plan to identify specific signaling steps that could be turned up or down and test targeted ways to shift those signals back toward protection. The work is coordinated across labs as a collaborative effort centered at the University of Chicago and partner sites.
Who could benefit from this research
Good fit: Ideal candidates would include adults with recent-onset type 1 diabetes, people at high risk (for example, autoantibody-positive), or donors willing to provide blood or pancreatic tissue samples for research.
Not a fit: People with long-standing type 1 diabetes who have little remaining beta-cell function or anyone seeking an immediate clinical treatment are unlikely to get direct benefit from this laboratory-focused program.
Why it matters
Potential benefit: If successful, this work could point to new ways to protect beta cells and slow or prevent the development of type 1 diabetes.
How similar studies have performed: Previous studies have found interferon-related molecular signatures in early type 1 diabetes and support targeting these pathways, but therapies that directly stop disease by modulating interferon signaling remain experimental.
Where this research is happening
CHICAGO, UNITED STATES
- UNIVERSITY OF CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MIRMIRA, RAGHAVENDRA G — UNIVERSITY OF CHICAGO
- Study coordinator: MIRMIRA, RAGHAVENDRA G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diabetes